CXCL10 and COVID-19: In contrast, an increase in CXCL10 (IP-10) by ∼100-fold was measured on the basolateral side of SARS-CoV-2-infected samples at 6 dpi, which has been reported as a biomarker of COVID-19 disease severity (Fig. 4H) (17).